Bafna Pharmaceuticals
Bafna Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Bafna Pharmaceuticals
Start SIPBafna Pharmaceuticals Investment Rating
-
Master Rating:
-
Bafna Pharmaceuticals has an operating revenue of Rs. 88.09 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 6% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 20 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 34 | 22 | 17 | 15 |
| Operating Expenses Qtr Cr | 31 | 19 | 15 | 16 |
| Operating Profit Qtr Cr | 4 | 3 | 2 | -1 |
| Depreciation Qtr Cr | 1 | 1 | 1 | 1 |
| Interest Qtr Cr | 1 | 0 | 0 | 0 |
| Tax Qtr Cr | 0 | 0 | 0 | 0 |
| Net Profit Qtr Cr | 3 | 2 | 1 | -1 |
Bafna Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 3
- Bearish Moving Average
- ___
- 13
- 20 Day
- 87.44
- 50 Day
- 91.87
- 100 Day
- 96.26
- 200 Day
- 103.27
- 20 Day
- 88.56
- 50 Day
- 93.02
- 100 Day
- 96.9
- 200 Day
- 103.31
Bafna Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 83.19 |
| Second Resistance | 84.72 |
| Third Resistance | 87.79 |
| RSI | 29.31 |
| MFI | 26.39 |
| MACD Single Line | -2.49 |
| MACD | -3.3 |
| Support | |
|---|---|
| First Resistance | 78.59 |
| Second Resistance | 75.52 |
| Third Resistance | 73.99 |
Bafna Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 3,043 | 304,300 | 100 |
| Week | 1,072 | 107,240 | 100 |
| 1 Month | 1,800 | 179,981 | 100 |
| 6 Month | 1,365 | 136,531 | 100 |
Bafna Pharmaceuticals Result Highlights
Bafna Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Bafna Pharmaceutical belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 71.22 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2021. Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698.| Market Cap | 190 |
| Sales | 88 |
| Shares in Float | 0.24 |
| No of funds | 1 |
| Yield |
| Book Value | 3.02 |
| U/D Vol ratio | 1 |
| LTDebt / Equity | 13 |
| Alpha | -0.18 |
| Beta | 0.36 |
Bafna Pharmaceuticals
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 90.02% | 90% | 90.12% | |
| Foreign Portfolio Investors | ||||
| Individual Investors | 5.61% | 5.62% | 5.5% | |
| Others | 4.37% | 4.38% | 4.38% |
Bafna Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mrs. S Hemalatha | Chairperson & Executive Director |
| Mr. Atul Sachdeva | Non Exe.Non Ind.Director |
| Mrs. Akila C Raju | Non Exe.Non Ind.Director |
| Ms. R Chitra | Ind. Non-Executive Director |
| Mr. B Kamlesh Kumar | Ind. Non-Executive Director |
| Mr. P K Sundaresan | Ind. Non-Executive Director |
Bafna Pharmaceuticals Forecast
Price Estimates
Bafna Pharmaceuticals FAQs
What is Share Price of Bafna Pharmaceuticals ?
Bafna Pharmaceuticals share price is ₹84 As on 30 March, 2023 | 07:55
What is the Market Cap of Bafna Pharmaceuticals ?
The Market Cap of Bafna Pharmaceuticals is ₹200.7 Cr As on 30 March, 2023 | 07:55
What is the P/E ratio of Bafna Pharmaceuticals ?
The P/E ratio of Bafna Pharmaceuticals is 40.5 As on 30 March, 2023 | 07:55
What is the PB ratio of Bafna Pharmaceuticals ?
The PB ratio of Bafna Pharmaceuticals is 3.2 As on 30 March, 2023 | 07:55